Follow
Jing Ning
Jing Ning
The University of Texas MD Anderson Cancer Center
Verified email at mdanderson.org
Title
Cited by
Cited by
Year
Complete surgical excision is essential for the management of patients with breast implant–associated anaplastic large-cell lymphoma
MW Clemens, LJ Medeiros, CE Butler, KK Hunt, MA Fanale, S Horwitz, ...
Journal of Clinical Oncology 34 (2), 160, 2016
4602016
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study.
Cancer Discov., 2018
443*2018
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
P Jayaprakash, M Ai, A Liu, P Budhani, T Bartkowiak, J Sheng, C Ager, ...
The Journal of clinical investigation 128 (11), 5137-5149, 2018
3022018
The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
P Williams, S Basu, G Garcia‐Manero, CS Hourigan, KA Oetjen, ...
Cancer 125 (9), 1470-1481, 2019
2532019
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
CD DiNardo, A Maiti, CR Rausch, N Pemmaraju, K Naqvi, NG Daver, ...
The Lancet Haematology 7 (10), e724-e736, 2020
2362020
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens
CA Lachowiez, S Loghavi, TM Kadia, N Daver, G Borthakur, ...
Blood advances 4 (7), 1311-1320, 2020
1262020
Analyzing length-biased data with semiparametric transformation and accelerated failure time models
Y Shen, J Ning, J Qin
Journal of the American Statistical Association 104 (487), 1192-1202, 2009
1252009
Comprehensive geriatric assessment of risk factors associated with adverse outcomes and resource utilization in cancer patients undergoing abdominal surgery
B Badgwell, J Stanley, GJ Chang, MHG Katz, HY Lin, J Ning, SV Klimberg, ...
Journal of surgical oncology 108 (3), 182-186, 2013
1222013
Malignancy‐associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes
GN Tamamyan, HM Kantarjian, J Ning, P Jain, K Sasaki, KL McClain, ...
Cancer 122 (18), 2857-2866, 2016
1202016
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia
NJ Short, G Montalban-Bravo, H Hwang, J Ning, MJ Franquiz, ...
Blood advances 4 (22), 5681-5689, 2020
1122020
Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
A Maiti, CR Rausch, JE Cortes, N Pemmaraju, NG Daver, F Ravandi, ...
Haematologica 106 (3), 894, 2021
962021
Phase IB/II study of nivolumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML)
N Daver, S Basu, G Garcia-Manero, JE Cortes, F Ravandi, EJ Jabbour, ...
Blood 128 (22), 763, 2016
792016
Next‐generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma
MT Tetzlaff, RR Singh, EG Seviour, JL Curry, CW Hudgens, D Bell, ...
The Journal of pathology 240 (1), 84-95, 2016
752016
Maximum likelihood estimations and EM algorithms with length-biased data
J Qin, J Ning, H Liu, Y Shen
Journal of the American Statistical Association 106 (496), 1434-1449, 2011
722011
Website usage and weight loss in a free commercial online weight loss program: retrospective cohort study
KO Hwang, J Ning, AW Trickey, CN Sciamanna
Journal of medical Internet research 15 (1), e11, 2013
682013
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.
blood, 2018
65*2018
Radiomics features of the primary tumor fail to improve prediction of overall survival in large cohorts of CT-and PET-imaged head and neck cancer patients
RB Ger, S Zhou, B Elgohari, H Elhalawani, DM Mackin, JG Meier, ...
PLoS One 14 (9), e0222509, 2019
642019
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia
A Maiti, CD DiNardo, SA Wang, J Jorgensen, TM Kadia, NG Daver, ...
Blood advances 5 (7), 1876-1883, 2021
632021
Identification of Novel Autoantibodies Associated with Psoriatic Arthritis
Yuan, Y., Qiu, J., Lin, Z.T., Li, W., Haley, C., Mui, U.N., Ning, J., Tyring ...
Arthritis & Rheumatology., 2019
632019
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment‐related mortality
A Maiti, W Qiao, K Sasaki, F Ravandi, TM Kadia, EJ Jabbour, NG Daver, ...
American journal of hematology 96 (3), 282-291, 2021
622021
The system can't perform the operation now. Try again later.
Articles 1–20